The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

February 14, 2022

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

February 10, 2022

Induction treatment with ibrutinib and rituximab was safe and active in patients with mantle cell lymphoma aged 65 years or younger, allowing for fewer cycles of subsequent chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone thereby reducing toxicity.

February 09, 2022

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

January 31, 2022

In honor of their notable contributions to the field of cancer research, Juan Fueyo, MD, and Victor Prieto, MD, PhD, from The University of Texas MD Anderson Cancer Center, have been named fellows of the American Association for the Advancement of Science.

January 28, 2022

Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.

January 28, 2022

Kanwal P.S. Raghav, MBBS, MD, discusses potential combinations with fam-trastuzumab deruxtecan-nxki in HER2-positive colorectal cancer.

January 27, 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the current state of circulating tumor DNA testing in colorectal cancer.

January 26, 2022

Debu Tripathy, MD, discusses key developments that may set the stage for new directions in care of breast cancer, including several areas of the treatment landscape on the cusp of change.

January 25, 2022

The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations.

January 25, 2022

Momelotinib provided a statistically significant benefit in terms of splenic symptoms, anemia, and splenic size in patients with myelofibrosis.

January 24, 2022

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.

January 24, 2022

Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.

January 24, 2022

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

January 24, 2022

The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.

January 22, 2022

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

January 20, 2022

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

January 15, 2022

Naval Daver, MD, discusses the latest developments in acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and follicular lymphoma.

January 13, 2022

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

January 11, 2022

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

January 11, 2022

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.